{"id":156322,"date":"2026-11-05T22:49:11","date_gmt":"2026-11-05T22:49:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/156322\/"},"modified":"2026-11-05T22:49:11","modified_gmt":"2026-11-05T22:49:11","slug":"novartis-cites-previously-unknown-tumor-cases-possibly-tied-to-gene-therapy-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/156322\/","title":{"rendered":"Novartis cites previously unknown tumor cases possibly tied to gene therapy"},"content":{"rendered":"<p class=\"author-bio\">Ed\u2019s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning <a href=\"https:\/\/www.statnews.com\/signup\/pharmalittle\/\" rel=\"nofollow noopener\" target=\"_blank\">Pharmalittle newsletter<\/a> and the afternoon <a href=\"https:\/\/www.statnews.com\/signup\/pharmalot\/\" rel=\"nofollow noopener\" target=\"_blank\">Pharmalot newsletter<\/a>.<\/p>\n<p class=\"wp-block-paragraph\">Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, a surprising development that has raised concerns among families, physicians, and patient advocacy groups.<\/p>\n<p class=\"wp-block-paragraph\">The cases, which for the moment are being seen as only a potential safety signal, were publicized on Thursday by an advocacy group and on a Facebook page after Novartis earlier this week disclosed the information to neurologists. One advocacy group, <a href=\"https:\/\/www.sma-europe.eu\/news\/information-regarding-recent-zolgensma-safety-concerns\" target=\"_blank\" rel=\"noopener nofollow\">SMA Europe, issued a statement<\/a> saying that regulatory authorities are now examining the cases.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">The drugmaker issued its own statement saying that since its treatment \u2014 called Zolgensma \u2014 was approved in 2019, it has received nine reports of tumors in previously treated patients. Of those, two cases to date showed evidence that the tumors may be linked to the treatment itself.\u00a0\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/11\/1793918950_561_stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Ed\u2019s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He&hellip;\n","protected":false},"author":2,"featured_media":156323,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[336,212,206,337,2421,339],"class_list":["post-156322","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-biotechnology","tag-gene-therapy","tag-novartis","tag-pharmaceuticals","tag-rare-diseases","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117566280145604544","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/156322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=156322"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/156322\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/156323"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=156322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=156322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=156322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}